Janssen will stop making injected, oral forms of antibiotic Levaquin

Johnson & Johnson's ($JNJ) Janssen Pharmaceuticals unit has notified the FDA that it has made a business decision to discontinue the production of the injected and oral forms of its antibiotic Levaquin. According to the FDA, no other explanation was given. The one-time substantial seller went off patent several years ago. The company has had to deal with thousands of lawsuits over claims that it didn't do enough to warn users about potential tendon injuries. Report | More

Suggested Articles

Just one week after inking a COVID-19 vaccine deal with the U.S. for 100 million doses, J&J reached a supply agreement twice that size with the EU.

AstraZeneca will work with the governments of Mexico and Argentina to produce hundreds of millions of doses of its COVID-19 vaccine hopeful.

Belgian CDMO Ajinomoto Bio-Pharma Services has been on a run in recent of years expanding its operations around the world.